Cost Effectiveness of Tofacitinib as Second Line Treatment vs Using Biological Therapies in the Treatment of Moderate Rheumatoid Arthritis After Failure of Dmards in Panama in 2014
Value in Health - United Kingdom
doi 10.1016/j.jval.2015.03.939
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2015
Authors
Publisher
Elsevier BV